Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Receivables - Other (2022 - 2025)

Historic Receivables - Other for Apellis Pharmaceuticals (APLS) over the last 4 years, with Q3 2025 value amounting to $6.5 million.

  • Apellis Pharmaceuticals' Receivables - Other rose 3178.7% to $6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year increase of 3178.7%. This contributed to the annual value of $4.5 million for FY2024, which is 4816.63% up from last year.
  • As of Q3 2025, Apellis Pharmaceuticals' Receivables - Other stood at $6.5 million, which was up 3178.7% from $5.9 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Receivables - Other registered a high of $6.5 million during Q3 2025, and its lowest value of $1.4 million during Q4 2022.
  • Over the past 4 years, Apellis Pharmaceuticals' median Receivables - Other value was $4.5 million (recorded in 2024), while the average stood at $4.0 million.
  • Its Receivables - Other has fluctuated over the past 5 years, first skyrocketed by 18171.57% in 2024, then skyrocketed by 3178.7% in 2025.
  • Apellis Pharmaceuticals' Receivables - Other (Quarter) stood at $1.4 million in 2022, then skyrocketed by 111.79% to $3.1 million in 2023, then skyrocketed by 48.17% to $4.5 million in 2024, then soared by 44.4% to $6.5 million in 2025.
  • Its last three reported values are $6.5 million in Q3 2025, $5.9 million for Q2 2025, and $6.1 million during Q1 2025.